- Home
- SACH vs MAIA Comparison
SACH vs MAIA Comparison
Compare SACH & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- MAIA
- Stock Information
- Founded
- SACH 2010
- MAIA 2018
- Country
- SACH United States
- MAIA United States
- Employees
- SACH N/A
- MAIA N/A
- Industry
- SACH Real Estate Investment Trusts
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- MAIA Health Care
- Exchange
- SACH Nasdaq
- MAIA Nasdaq
- Market Cap
- SACH 61.5M
- MAIA 52.7M
- IPO Year
- SACH 2017
- MAIA 2022
- Fundamental
- Price
- SACH $1.19
- MAIA $1.99
- Analyst Decision
- SACH Buy
- MAIA
- Analyst Count
- SACH 2
- MAIA 0
- Target Price
- SACH $2.25
- MAIA N/A
- AVG Volume (30 Days)
- SACH 512.1K
- MAIA 251.4K
- Earning Date
- SACH 11-14-2024
- MAIA 11-12-2024
- Dividend Yield
- SACH 19.92%
- MAIA N/A
- EPS Growth
- SACH N/A
- MAIA N/A
- EPS
- SACH N/A
- MAIA N/A
- Revenue
- SACH $10,951,064.00
- MAIA N/A
- Revenue This Year
- SACH N/A
- MAIA N/A
- Revenue Next Year
- SACH N/A
- MAIA N/A
- P/E Ratio
- SACH N/A
- MAIA N/A
- Revenue Growth
- SACH N/A
- MAIA N/A
- 52 Week Low
- SACH $1.15
- MAIA $0.99
- 52 Week High
- SACH $4.64
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- SACH 25.83
- MAIA 41.94
- Support Level
- SACH $1.15
- MAIA $1.92
- Resistance Level
- SACH $1.48
- MAIA $2.16
- Average True Range (ATR)
- SACH 0.07
- MAIA 0.21
- MACD
- SACH 0.01
- MAIA 0.01
- Stochastic Oscillator
- SACH 11.89
- MAIA 20.00
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.